Wegovy weight loss: real results from clinical trials and UK practice

The STEP clinical trial programme is the largest evidence base for Wegovy (semaglutide 2.4 mg) and provides robust data on weight loss outcomes.

STEP 1 (adults without diabetes):

• Average weight loss of 14.9 per cent of body weight over 68 weeks
• Compared to 2.4 per cent in the placebo group
• More than one-third of participants lost 20 per cent or more of their body weight

STEP 2 (adults with type 2 diabetes):

• Average weight loss of 9.6 per cent over 68 weeks
• Patients with diabetes typically lose less weight due to the metabolic effects of their condition

STEP 3 (with intensive behavioural therapy):

• Average weight loss of 16 per cent over 68 weeks
• Combining Wegovy with structured lifestyle support enhanced results

STEP 4 (withdrawal study):

• Patients who continued Wegovy maintained their weight loss
• Those who switched to placebo after 20 weeks regained approximately two-thirds of the weight they had lost
• This underscores the importance of continued treatment for sustained results

These trials demonstrate that Wegovy produces significantly greater weight loss than diet and exercise alone, which is why NICE approved it for use in the NHS weight management pathway.

Understanding the typical weight loss timeline can help set realistic expectations and keep you motivated throughout your treatment.

Month 1 (0.25 mg dose):

• Most patients begin to notice reduced appetite within the first week
• Weight loss is typically modest, around 1 to 2 kg, as you are on the lowest dose
• Side effects such as nausea may be present but are usually mild

Months 2 to 4 (0.5 mg to 1 mg doses):

• Weight loss accelerates as the dose increases through the escalation schedule
• Average weight loss of 3 to 5 per cent of starting body weight by month 4
• Appetite suppression becomes more noticeable

Months 5 to 9 (1.7 mg to 2.4 mg doses):

• This is typically the period of most rapid weight loss
• Patients often lose 1 to 2 per cent of body weight per month
• Physical improvements such as reduced waist circumference and improved energy become apparent

Months 10 to 16:

• The rate of weight loss begins to slow as your body approaches a new equilibrium
• Total average weight loss of 12 to 15 per cent of starting body weight
• Metabolic improvements including better blood sugar, blood pressure, and cholesterol levels are well established

Beyond 16 months:

• Weight tends to stabilise with continued treatment
• Ongoing lifestyle changes are essential to maximise and maintain results
• Regular follow-up with your weight management team helps sustain progress

Individual weight loss with Wegovy varies considerably. Understanding the factors that influence your results can help you optimise your treatment.

Factors associated with greater weight loss:

• Adherence to the dose escalation schedule: completing the full escalation and reaching the 2.4 mg maintenance dose
• Dietary changes: reducing calorie intake and choosing nutrient-dense foods
• Physical activity: regular exercise, even moderate walking, enhances weight loss and preserves muscle mass
• Behavioural support: structured weight management programmes with regular coaching produce better outcomes
• Starting weight: patients with a higher starting BMI may lose more absolute weight

Factors that may limit weight loss:

• Type 2 diabetes: metabolic changes associated with diabetes can reduce the amount of weight lost
• Medications that promote weight gain: some antidepressants, antipsychotics, corticosteroids, and insulin can counteract weight loss
• Hormonal factors: thyroid disorders, polycystic ovary syndrome, and menopause can affect results
• Sleep and stress: poor sleep quality and chronic stress are associated with reduced weight loss
• Genetics: individual variation in GLP-1 receptor sensitivity means some people respond more strongly than others

NICE guidance recommends that treatment should be reviewed after 6 months on the maintenance dose.

If a patient has not achieved at least 5 per cent weight loss, the decision to continue should be reassessed.

The benefits of Wegovy extend well beyond the number on the scales. Clinical trials have demonstrated significant improvements across multiple health markers.

Cardiovascular health:

• The SELECT trial showed a 20 per cent reduction in major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) in patients taking semaglutide 2.4 mg
• Reductions in systolic blood pressure of 4 to 6 mmHg on average
• Improvements in cholesterol profiles, including reduced triglycerides and increased HDL cholesterol

Metabolic health:

• Improved blood sugar control, with many pre-diabetic patients returning to normal glucose levels
• Reduced HbA1c levels in patients with type 2 diabetes
• Decreased liver fat content, which may benefit patients with non-alcoholic fatty liver disease

Quality of life:

• Improved physical functioning and mobility
• Reduced joint pain and improved exercise tolerance
• Better sleep quality, including improvements in obstructive sleep apnoea
• Improved body image and psychological wellbeing

Other benefits:

• Reduced waist circumference, a key marker of visceral fat
• Potential reduction in the risk of obesity-related cancers (long-term data still emerging)
• Improvements in fertility outcomes in women with obesity-related subfertility

These broader health improvements reinforce why weight management is about much more than aesthetics. Losing 10 to 15 per cent of body weight can transform your overall health profile.

Sustaining weight loss after Wegovy treatment is one of the most important aspects of your journey.

The STEP 4 trial clearly showed that stopping semaglutide leads to weight regain, so planning for the long term is essential.

While on Wegovy:

• Build sustainable eating habits rather than following restrictive diets
• Focus on protein-rich foods to preserve lean muscle mass during weight loss
• Establish a regular exercise routine that you enjoy and can maintain
• Attend regular follow-up appointments with your weight management team

If treatment is stopped:

• Weight regain is common and expected. This is not a failure but a biological response
• The rate of regain varies, but studies suggest approximately two-thirds of lost weight may return within a year
• Continuing the lifestyle changes established during treatment can slow the rate of regain

Long-term treatment considerations:

• NICE recognises that obesity is a chronic condition that may require long-term pharmacological treatment
• Your prescriber will review your treatment regularly and discuss whether continuation is appropriate
• Some patients may benefit from intermittent courses of treatment

Building a sustainable lifestyle:

• Work with a dietitian to develop a balanced eating plan
• Aim for at least 150 minutes of moderate-intensity physical activity per week
• Address psychological factors such as emotional eating or stress-related food choices
• Consider joining a support group or community programme for ongoing motivation